Center for Global Health R&D Policy Assessment

Follow us on:

Blogs tagged: product development partnerships

Elizabeth Poll
Posted by Elizabeth Poll
Nov 17 2011

Beyond ACTs: what medicines will it take to eradicate malaria?

MMV discusses the necessity for continued malaria R&D

Medicines for Malaria Venture - Logo

Today, in 2011, we are a far cry from the empty malaria medicine pipeline of the 1990s. There are two WHO-prequalified artemisinin-based combination therapies (ACTs) available (artemether/lumefantrine and artesunate/amodiaquine) and two more due to be launched in 2012 (Eurartesim® [dihydroartemisinin/piperaquine] from sigma-tau Industrie Farmaceutiche Riunite and Medicines for Malaria Venture [MMV] and Pyramax® [pyronaridine/artesunate] from Shin-Poong Pharmaceuticals and MMV). Additionally, we now have a WHO-prequalified treatment for severe malaria at our disposal.

Margaret McGlynn
Posted by Margaret McGlynn
Oct 11 2011

Using IP to accelerate product development and ensure access

A guest blog post by Margaret McGlynn, President and CEO of the International AIDS Vaccine Initiative

Photo courtesy IAVI

Did you enjoy our PDP mini-series from August? This is a guest blog post from the International AIDS Vaccine Initiative (IAVI) that gives a deeper insight on how IAVI handles IP issues.

Bernard Pécoul
Posted by Bernard Pécoul
Aug 16 2011

Partnering for R&D for the Most Neglected

Part three of the PDP mini-series: Guest blog from DNDi

DNDi Logo

This is the third part to our Product Development Partnership (PDP) mini-series.

Jennifer Woolley
Posted by Jennifer Woolley
Aug 8 2011

Dedicated to Developing New TB Vaccines for the World

Part two of the PDP mini-series: Guest blog from Aeras

Aeras Logo

This is the second part to our Product Development Partnership (PDP) mini-series. Here, Jennifer Woolley from Aeras discusses their PDP experience with tuberculosis vaccine development.

Tuberculosis is known as a disease of poverty.

Marc LaForce
Posted by Marc LaForce
Aug 2 2011

Working Together, Africa Receives the Best

The first guest blog post on our PDP mini-series

PATH MVP logo

Last month, we reported on our attendance at the Bill & Melinda Gates Foundation Product-Development Partnership (PDP) Forum “Partnering for Impact.” We discussed the role that our Center plays in this larger picture of neglected disease and global health research and development (R&D) field as well as reflected on the journey PDPs have taken and what might lie ahead for them.

Edith Han
Posted by Edith Han
Jun 17 2011

R&D Financing and Incentives at the PDP Forum

A Q&A session with Robert Hecht on his attendance at the BMGF PDP Forum

A team from R4D’s Center for Global Health R&D Policy Assessment, consisting of Managing Director Robert Hecht, Program Director Jean Arkedis, and Senior Consultant Paul Wilson attended the Bill & Melinda Gates Foundation’s (BMFG) Product Development Partnership (PDP) Forum, from May 24-26 in Bellevue, Washington.

This year’s Forum brought together more than 250 persons including the CEOs and other senior managers from the 15 PDPs that are funded by the BMGF to develop new vaccines, drugs, diagnostic tests, and vector control me

Robert Hecht
Posted by Robert Hecht
Jun 2 2010

Biotechs and non-profit drug developers learning to dance together

How can best practices be multiplied?

At the annual Partnering Forum hosted by BioVentures for Global Health (BVGH) that I attended in Chicago on May 3, the session on “Making It Work: Compelling Business Models for Global Health Product Development” really caught my attention. That’s because the session panel gave some great examples of how non-profit organizations working to create new drugs, vaccines, and diagnostics for the neglected diseases of poor countries can team up with scientists and firms in the North and the South to make things happen.

In the session, Dr.

Kimberly Manno Reott
Posted by Kimberly Manno Reott
May 19 2010

The Emerging PDP+ Fund

On the evening of May 17th in Geneva, three prominent global health organizations announced their intention to develop a new PDP funding mechanism to support R&D for neglected diseases. The core proponents – The International AIDS Vaccine Initiative, the George Institute for International Health, and Novartis – are calling this new idea the PDP+ Fund.